Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome

BMC Cancer

Table 1 IGFBP7 expression, mutation and genotyping analyses relative to EOC cell lines features and growth characteristics

Cell lines	Histopathology	Grade	Stage	Source	Age	TP53mutation status*	Growth in soft agar*	Spheroid formation*	Tumour formation in nude mouse*		IGFBP7mutation	GenotypeIGFBP7locus	IGFBP7methylation	IGFBP7transcript expression	IGFBP7 protein detection in total cell lysate
Cell lines	Histopathology	Grade	Stage	Source	Age	TP53mutation status*	Growth in soft agar*	Spheroid formation*	Subcutaneous	Intraperitoneal	IGFBP7mutation	GenotypeIGFBP7locus	IGFBP7methylation	IGFBP7transcript expression	IGFBP7 protein detection in total cell lysate
TOV2223G	Serous papillary cystadenocarcinoma	3	III-C	Tumor	89	Positive	Yes	No	No	No	No	LOH	Yes	Low	No
OV1946	Serous papillary cystadenocarcinoma	3	III-C	Ascites	75	Positive	Yes	Semi-compact	No	Yes	No	LOH	No	Low	No
TOV1946	Serous papillary cystadenocarcinoma	3	III-C	Tumor	75	Positive	Yes	Aggregate	No	Yes	No	LOH	No	Low	No
TOV81D	Serous papillary adenocarcinoma	1-2	III-C	Tumor	66	Negative	No	No	No	No	No	HET	No	High	High
TOV112D	Endometrioid carcinoma	3	III-C	Tumor	42	Positive	Yes	Yes	Yes	Yes	No	LOH	Yes	No	No
TOV21G	Clear cell carcinoma	3	III	Tumor	62	Negative	Yes	Yes	Yes	Yes	No	HET	No	High	Low
OV90	Adenocarcinoma	3	III-C	Ascites	64	Positive	Yes	Yes	Yes	Yes	No	AI	No	Low	No

*From Provencher et al. [19]; Ouellet et al. [46]; Cody et al [15]. n/d: not determined, LOH: Loss of heterozygosity, HET: heterozygote, AI: allelic imbalance.

ISSN: 1471-2407